Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
Crossref DOI link: https://doi.org/10.1186/s12885-015-1552-y
Published Online: 2015-07-21
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kim, Seung Tae
Jang, Kee-Taek
Lee, Su Jin
Jang, Hye-Lim
Lee, Jeeyun
Park, Se Hoon
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
Park, Joon Oh
License valid from 2015-07-21
Article History
Received: 29 April 2014
Accepted: 14 July 2015
First Online: 21 July 2015